Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Mar 7, 2014; 20(9): 2218-2223
Published online Mar 7, 2014. doi: 10.3748/wjg.v20.i9.2218
Opioid growth factor and the treatment of human pancreatic cancer: A review
Ian S Zagon, Patricia J McLaughlin
Ian S Zagon, Patricia J McLaughlin, Department of Neural and Behavioral Sciences, Pennsylvania State University College of Medicine, Hershey, PA 17033, United States
Author contributions: Zagon IS and McLaughlin PJ contributed equally to this review.
Supported by Grants from NIH in part, Philip Morris United States, and The Pennsylvania Department of Heath, as well as generous gifts from the Paul I and Anna E Shockey Family Foundation
Correspondence to: Patricia J McLaughlin, Professor, Department of Neural and Behavioral Sciences, Pennsylvania State University College of Medicine, MC-H109, 500 University Drive, Hershey, PA 17033, United States. pxm9@psu.edu
Telephone: +1-717-5316414 Fax: +1-717-5315003
Received: August 28, 2013
Revised: January 2, 2014
Accepted: January 19, 2014
Published online: March 7, 2014
Core Tip

Core tip: Opioid growth factor (OGF) biotherapy for human pancreatic cancer is based on inhibition of DNA synthesis by upregulation of cyclin-dependent inhibitory kinases. Preclinical studies using human pancreatic cancer cell lines have demonstrated that OGF interaction with its selective receptor OGF receptor (OGFr) is a physiological determinant of cell proliferation. Addition of OGF to standard chemotherapies enhances the efficacy of treatment. Studies in nude mice confirm that the OGF-OGFr axis regulates pancreatic cancer progression. Clinical trials using OGF for treatment of patients with unresectable pancreatic tumors reveal that OGF is a novel endogenous opioid that is safe, non-toxic, elicits negligible side effects and reduces pancreatic tumor size in persons who have failed other therapies.